Solutions for tissue engineering and methods of use

• US 9,682,173 B2
• Filed: 06/11/2009
• Issued: 06/20/2017
• Est. Priority Date: 06/11/2008
• Status: Active Grant

• Current Assignee: Children's Mercy Hospital
• Original Assignee: Children's Mercy Hospital
• Inventors: Hopkins, Richard
• Primary Examiner(s): SINGH, ANOOP KUMAR
• Application Number:
  US12/483,196
• Publication Number:
  US 20100035344A1
• Time in Patent Office: 2,931 Days
• CPC Class Codes: A61L 2430/40 Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3695 characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this A61L27/3687, A61L27/3691 take precedence
• CPC Class Codes: C12N 2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0068 General culture methods using substrates for specific animal cell type C12N5/06

Abstract

The present invention provides for solutions and methods of preparing a decellularized tissue for recellularization. The solutions provide collagen conditioning to restore collagen triple helix structure, strengthening of the collagen structure of the tissue, and biologically preparing the decellularized tissue by placing it in an environment that promotes recellularization. Methods and solutions for recellularization of a decellularized tissue, in accordance with the present invention, are also provided.

Claims

1. A composition comprising decellularized tissue suspended in a solution comprising:

i) −

20 % to 60 % of ethyl alcohol;

ii) 0.03 to 0.75 M of lauryl alcohol;

iii) 0.03 to 0.75 M of myristyl alcohol; and

iv) 30 to 300 μ

g/L of hyaluronan high molecular weight (HMW) salt.

2. The solution of claim 1, further comprising citric acid and/or heparain.

3. The solution of claim 1, further comprising glycerol.

5. The method according to claim 1, further comprising normal saline.

4. A solution for the treatment of decellularized tissue consisting essentially of:

i) 20 % to 60 % of ethyl alcohol;

ii) 0.03 to 0.75 M of lauryl alcohol;

iii) 0.03 to 0.75 M of myristyl alcohol;

iv) 30 to 300 μ

g/L of hyaluronan HMW salt;

v) about 1 to 9 g/L of citric acid;

vi) normal saline; and

vii) heparin.